Programs & products | Innate Pharma

Innate Pharma highlights ANKET® abstracts selected for the EHA 2025 congress

May 15, 2025

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in...

Innate Pharma reports first quarter 2025 business update and financial results

May 13, 2025

€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET ® program in autoimmune indications First patient dosed in a Phase 1 study...

Innate Pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at the AACR 2025 annual meeting

April 29, 2025

IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated superior preclinical anti-tumor activity...

Innate Pharma regains its rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company

April 23, 2025

Innate to regain its rights on CD123 targeting ANKET ® SAR443579 (SAR’579) /IPH6101 currently in development for AML Potential investment of up to €15M by Sanofi in Innate Pharma through a capital...

Innate Pharma reports full year 2024 financial results and business update

March 27, 2025

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2...

Innate Pharma highlights antibody drug conjugate IPH4502 abstract selected for the AACR 2025 annual meeting

March 26, 2025

IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated preclinical anti-tumor efficacy...

Innate Pharma announces first patient dosed in Phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors

January 27, 2025

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today...

IPH4502, Antibody-drug conjugate

What is IPH4502?

IPH4502 is a novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4.

Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.

In non-clinical models, IPH45 was well tolerated and shows anti-tumor efficacy in vitro and in vivo.

Read more about IPH4502, Antibody-drug conjugate

Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024 from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma

December 9, 2024

Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“...

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announce up to $7.9m investment from IFLI to support IPH6501 development in Follicular Lymphoma

December 6, 2024

Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will be...